Overview

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ophthalmic Consultants of Boston
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept